Eli Lilly and (LLY) Q3 2026 Earnings Call: Guidance and Outlook
The company updated its full-year 2026 financial guidance, reflecting strong underlying performance across its portfolio. Formal 2027 guidance will be provided during the Q4 earnings call in January.
About Eli Lilly and. Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. , 70/30, N, R, U-500).
Expects sustained volume growth in the incretin market and the full-year impact of the Medicare GLP-1 Bridge access and the launch of Foundayo in type 2 diabetes.
International Revenue
Expects Mounjaro's leadership position to continue and the launch of Foundayo to drive additional market growth.
Pricing
Expects net realized price to be a headwind, which will be more than offset by volume growth.
One-time items
2026 revenue benefited from approximately $2 billion of one-time items that are not expected to recur.
Dombey's summary of the Eli Lilly and Q3 2026 earnings call held Oct 29, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
